Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 693.35

-0.2%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	9/24/2018 11:37:50 AM
	of 3559

RE:ANAB. anti-IL33 Abs (ANB020, Etokimab) competitor to REGN3500 finance.yahoo.com In this trial single dose was, 300 mg. Ongoing/planed 4w and 8w intervals: clinicaltrials.gov, clinicaltrials.gov Relative to 2w interval for REGN3500 (now in Sanofi control ): clinicaltrials.gov , and (COPD) clinicaltrials.gov So, my question/concern is how competitive is REGN3500??? Based on pre-clinical data both Abs seems equally potent. However, why REGN can not generate HUMAN Abs with longer t1/2, longer therapeutic duration????

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next